- Home
- MHLD vs TLSI Comparison
MHLD vs TLSI Comparison
Compare MHLD & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHLD
- TLSI
- Stock Information
- Founded
- MHLD 2007
- TLSI 2010
- Country
- MHLD Bermuda
- TLSI United States
- Employees
- MHLD N/A
- TLSI N/A
- Industry
- MHLD Property-Casualty Insurers
- TLSI Medical Specialities
- Sector
- MHLD Finance
- TLSI Health Care
- Exchange
- MHLD Nasdaq
- TLSI Nasdaq
- Market Cap
- MHLD 137.1M
- TLSI 150.3M
- IPO Year
- MHLD 2008
- TLSI N/A
- Fundamental
- Price
- MHLD $1.21
- TLSI $4.93
- Analyst Decision
- MHLD
- TLSI Strong Buy
- Analyst Count
- MHLD 0
- TLSI 6
- Target Price
- MHLD N/A
- TLSI $11.75
- AVG Volume (30 Days)
- MHLD 249.9K
- TLSI 33.1K
- Earning Date
- MHLD 03-11-2025
- TLSI 11-14-2024
- Dividend Yield
- MHLD N/A
- TLSI N/A
- EPS Growth
- MHLD N/A
- TLSI N/A
- EPS
- MHLD N/A
- TLSI N/A
- Revenue
- MHLD $89,074,000.00
- TLSI $26,891,000.00
- Revenue This Year
- MHLD N/A
- TLSI $60.96
- Revenue Next Year
- MHLD N/A
- TLSI $53.65
- P/E Ratio
- MHLD N/A
- TLSI N/A
- Revenue Growth
- MHLD 20.80
- TLSI 67.90
- 52 Week Low
- MHLD $1.16
- TLSI $3.50
- 52 Week High
- MHLD $2.27
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- MHLD 43.16
- TLSI 56.22
- Support Level
- MHLD $1.16
- TLSI $4.53
- Resistance Level
- MHLD $1.33
- TLSI $4.92
- Average True Range (ATR)
- MHLD 0.13
- TLSI 0.29
- MACD
- MHLD 0.00
- TLSI -0.02
- Stochastic Oscillator
- MHLD 9.09
- TLSI 50.63
About MHLD Maiden Holdings Ltd.
Maiden Holdings Ltd provides reinsurance products and services to regional and specialty property and casualty insurers. The company operates in two segments: AmTrust Reinsurance and Diversified Reinsurance. The AmTrust Reinsurance segment provides products that cover workers' compensation, commercial package, commercial auto, and extended warranty. The Diversified Reinsurance segment provides small and midsize regional and specialty insurers with reinsurance capital products. Its revenues also include fee income earned from both its GLS business and IIS business as well as income generated from its investment portfolio.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.